Akademik Veri Yönetim Sistemi
ISOPS 14th International Symposium on Pharmaceutical Sciences, Ankara, Türkiye, 25 - 28 Haziran 2024, ss.292, (Özet Bildiri)
Introduction: Proniosomes are dry powder formulations created from
non-ionic surfactants and water-soluble carrier particles. When exposed to
water or biological fluids, proniosomes convert into niosomes (1). Proniosomes
can potentially enhance pulmonary drug delivery by improving the flow and
distribution of drugs (2). This study explores the development of
proniosomal dry powder inhaler formulations for targeting the lungs, using
various methods and optimizing aerodynamic particle size.
Materials and Methods In this research, proniosome formulations
without active pharmaceutical ingredients (API) were prepared using the slurry
and thin film-hydration methods. Inhalation-grade lactose, Lactohale LH 300,
supplied by DFE Pharma, served as the water-soluble carrier. Span 60, a
non-ionic surfactant from Sigma Aldrich, and cholesterol from Amresco were used
to form the niosome structure. Magnesium stearate (MgSt) from Sigma Aldrich was
added to the formulation to prevent aggregation. A Buchi rotavapor was employed
for the slurry and thin film hydration methods, and a Teknosem lyophilizer was
used for lyophilization. Ultrasonic bath, vortex, and probe-sonicator
techniques were applied to reduce particle size. The resulting dry powder
formulations were sieved using 200 mesh (77 µm) sieves. Particle size analysis
of the proniosomes was conducted using laser diffraction with the Sympatec
Helos H0728 device, calculating Dv10, Dv50, Dv90, and span values. Niosome
particle size, polydispersity index (PI), and zeta potential were measured
using a Malvern Zetasizer Pro.
Results: The
average proniosome particle size (Dv50) for formulations produced via the
slurry and thin film hydration methods was approximately 5 µm. Niosome particle
sizes ranged from 1 to 3 µm, with PI values between 0.200 and 0.500 and zeta
potential values below -40 mV. Results from measurements with the New
Generation Impactor (NGI) device will be included.
Conclusions: Laser diffraction measurements showed that the
dry powder formulations have particle sizes suitable for inhalation. Prototype blank
formulations, to which APIs can be added, have been successfully prepared. The
study concludes that further optimization will be more straightforward after
incorporating the API.
Acknowledgements
This study was
supported by Ankara University Scientific Research Projects Commission
under the grant no: TDK-2024-3297.
References:
1.
Bayindir Z, Yuksel N (2015). Provesicles as Novel Drug
Delivery Systems. Current Pharmaceutical Biotechnology,16(4):344–364.
2.
Gamal A, Saeed H, Sayed O M, Kharshoum R M, Salem H F (2020). Proniosomal Microcarriers:
Impact of Constituents on the Physicochemical Properties of Proniosomes as a
New Approach to Enhance Inhalation Efficiency of Dry Powder Inhalers. AAPS
PharmSciTech, 21:156.